Postoperative Nausea & Vomiting (PONV)
Postoperative nausea and vomiting affects approximately 30% of unselected patients under general anesthesia (range 10–79% by risk profile) and is rated by patients as equally distressing as postoperative pain.[1][2] For the reconstructive urologist, PONV has two particular consequences that matter beyond patient satisfaction: delayed return of bowel function (a central ERAS metric after cystectomy and other major abdominal reconstruction) and unplanned hospital admission after ambulatory urology. This article covers the Apfel risk stratification, multimodal prophylaxis algorithm, drug-by-drug selection, and breakthrough / rescue management.
See also: Anesthesia, Analgesia, ERAS, Constipation, Steroids (for the dexamethasone antiemetic dose).
Risk Stratification — the Apfel Score
The dominant bedside risk tool. Four patient-anesthesia variables, one point each:
| Risk factor | Point |
|---|---|
| Female sex | 1 |
| Non-smoker | 1 |
| History of PONV or motion sickness | 1 |
| Expected postoperative opioid use | 1 |
| Apfel score | 24-h PONV risk | Recommended prophylaxis |
|---|---|---|
| 0 | ~10% | None required |
| 1 | ~20% | Consider monotherapy |
| 2 | ~40% | Dual prophylaxis |
| 3 | ~60% | Triple prophylaxis |
| 4 | ~80% | Triple prophylaxis + TIVA + regional anesthesia if feasible |
A strong argument from modern guidelines: because antiemetics are cheap and safe, liberal multimodal prophylaxis for all patients (essentially treating every general-anesthesia patient as if they were Apfel ≥2) is now widely endorsed.[1][5]
Anesthetic / Surgical Factors
Beyond the Apfel variables:[1][3][4]
- Volatile anesthetics (vs TIVA with propofol)
- Nitrous oxide >1 h
- Longer case duration
- Laparoscopic surgery
- Total blood loss (identified by ML analysis as the strongest contributor)
- Total infusion volume
- Lateral positioning
- Lumbar epidural
Pediatric-Specific Risk Factors[3]
- Age >3 years
- History of PONV or motion sickness
- Family history of PONV
- Post-pubertal girls
- Strabismus surgery, adenotonsillectomy, otoplasty
- Surgery duration >30 minutes
- Volatile anesthetics
- Anticholinesterases
- Long-acting opioids
For pediatric reconstructive urology (hypospadias repair, ureteral reimplantation, orchiopexy), the baseline antiemetic approach is often dual prophylaxis independent of a formal Apfel analog.
Non-Pharmacologic Mitigation
Anesthetic-technique choices that reduce PONV independent of drug prophylaxis:[1][5]
- Propofol-based TIVA instead of volatile anesthetic (reduced PONV, improved patient satisfaction; higher cost the main barrier)
- Regional anesthesia when feasible
- Minimize perioperative opioid through multimodal analgesia (see Analgesia)
- Avoid nitrous oxide in prolonged cases
- Adequate IV hydration — hypovolemia worsens PONV
- Avoid gastric distension during mask ventilation
Pharmacologic Prophylaxis
The Core Principle
Multimodal antiemetic prophylaxis (≥2 drugs from different classes) is superior to any single agent.[1][5] Each antiemetic independently reduces PONV by roughly 25%.[2] The strategy is additive blocks of different receptor pathways.
First-Line Combination
Dexamethasone + 5-HT₃ antagonist (ondansetron most common).[1][3][5]
- Dex hits corticosteroid pathway; ondansetron hits serotonin.
- Both are cheap and safe.
- Triple regimens add a third class — typically droperidol (D₂), scopolamine (anticholinergic), or aprepitant (NK₁).
Dosing
| Agent | Class | Typical dose |
|---|---|---|
| Dexamethasone | Corticosteroid | 4–8 mg IV at induction |
| Ondansetron | 5-HT₃ antagonist | 4 mg IV (or 8 mg oral dissolving tablet) |
| Granisetron | 5-HT₃ antagonist | 0.35–3 mg IV |
| Palonosetron | Long-acting 5-HT₃ | 0.075 mg IV |
| Droperidol | D₂ antagonist | 0.625–1.25 mg IV (QT monitoring) |
| Haloperidol | D₂ antagonist | 0.5–1 mg IV |
| Metoclopramide | D₂ antagonist (prokinetic) | 10 mg IV (weaker as antiemetic, useful as prokinetic) |
| Scopolamine | Anticholinergic | Transdermal patch evening before / morning of |
| Aprepitant | NK₁ antagonist | 40 mg PO preop |
| Fosaprepitant | NK₁ antagonist | 150 mg IV |
| Promethazine | H₁ antagonist | 6.25–12.5 mg IV |
| Dimenhydrinate | H₁ antagonist | 50 mg IV |
Best single agents for preventing vomiting (Cochrane network meta-analysis, at least moderate-certainty evidence):[2][6]
- Aprepitant 40 mg PO
- Ramosetron 0.3 mg IV
- Granisetron 0.35–3 mg IV
- Dexamethasone 4–8 mg IV
- Ondansetron 4 mg IV
- Droperidol 0.625–1.25 mg IV
- Fosaprepitant
Prophylaxis Algorithm by Apfel Score
| Apfel | Regimen |
|---|---|
| 0 | No prophylaxis required; TIVA or regional if clinical context favors |
| 1 | Single agent — dexamethasone 4–8 mg or ondansetron 4 mg |
| 2 | Dexamethasone 4–8 mg + ondansetron 4 mg |
| 3 | Triple: dexamethasone + ondansetron + droperidol 0.625 mg (or scopolamine patch, or aprepitant) |
| 4 | Triple + TIVA + consider aprepitant + regional analgesia |
Caveats by Drug Class
- 5-HT₃ antagonists — better for preventing vomiting than nausea; headache and constipation common.
- D₂ antagonists (droperidol, haloperidol) — extrapyramidal symptoms, sedation, QT prolongation (droperidol FDA black-box warning, re-licensed in Europe at low doses).[2]
- Dexamethasone 4–8 mg — transient hyperglycemia (monitor in diabetics — see Diabetes); no SSI increase from single perioperative dose; stacks with a stress-dose regimen — do not give extra in patients already on stress-dose steroids.
- Antihistamines / scopolamine — sedation, dry mouth, urinary retention (relevant caution in urology), confusion in the elderly.
- Midazolam — cautioned against as an antiemetic because of sedation overhang; use only when benzodiazepine is independently indicated.[3]
- NK₁ antagonists — useful but expensive; best evidence is aprepitant PO preop.
Breakthrough / Rescue PONV
For PONV despite prophylaxis:[7]
- Use a drug from a different class than the prophylactic agents already given.
- Ondansetron 4 mg IV is effective for treating active vomiting if not already used prophylactically.
- Add a second or third agent from yet another class if needed.
- Scopolamine patch for sustained nausea extending beyond the PACU.
- Address modifiable precipitants — opioid titration, NG tube, ileus, dehydration.
Do not simply re-dose the same class — redosing ondansetron after ondansetron prophylaxis rarely works.
Adverse-Effect Matrix
| Class | Key adverse effects |
|---|---|
| 5-HT₃ | Headache, constipation; QTc at high dose |
| D₂ (droperidol, haloperidol, metoclopramide) | EPS, sedation, QT prolongation |
| Corticosteroids | Transient hyperglycemia |
| Antihistamines | Sedation, dry mouth, urinary retention, visual disturbance |
| Anticholinergics (scopolamine) | Dry mouth, visual disturbance, sedation, confusion in elderly |
| NK₁ | Dizziness, headache |
The urinary retention caveat matters particularly in older male urologic patients — an antihistamine antiemetic can push a borderline retention patient into acute urinary retention postoperatively.
Clinical Consequences of PONV
- Delayed PACU discharge
- Unplanned admission after ambulatory surgery
- Delayed return of oral intake — directly undermines the ERAS bowel-function recovery target
- Increased healthcare cost
- Rare but serious: aspiration pneumonia, Boerhaave syndrome, severe subcutaneous emphysema[2]
- Decreased patient satisfaction scores (HCAHPS, etc.)
Enhanced-recovery protocols that incorporate multimodal PONV prophylaxis reduce PONV rates and readmission after colorectal surgery[1][5]; the same principle applies to cystectomy and major abdominal reconstructive urology.
GU-Specific Considerations
- Radical cystectomy / urinary diversion — dual or triple prophylaxis is standard; avoid antihistamines (urinary retention interference with diversion function). Alvimopan (for ileus) does not replace antiemetic prophylaxis.
- Robotic pelvic surgery (RARP, cystectomy) — steep Trendelenburg and CO₂ insufflation both elevate PONV risk; triple prophylaxis reasonable.
- Ambulatory urology (cystoscopy, TURP/HoLEP, orchiopexy, outpatient sling) — PONV drives unplanned admission; dual prophylaxis is routine.
- Post-diversion feeding intolerance — the differential diagnosis is PONV vs partial SBO vs ileus vs conduit obstruction; investigate before escalating antiemetics.
- Pediatric hypospadias / reimplantation — dual prophylaxis (dexamethasone + ondansetron) is standard.
Key Recommendations
- Risk-stratify every general-anesthesia patient with the Apfel score.
- Multimodal prophylaxis ≥2 agents from different classes is superior to any single agent.
- Dexamethasone 4–8 mg + ondansetron 4 mg at induction is the default dual prophylaxis.
- Triple prophylaxis (add droperidol, scopolamine, or aprepitant) for Apfel ≥3.
- TIVA + regional anesthesia for Apfel 4 or prior PONV history.
- Rescue with a different drug class — do not redose the same class.
- Avoid antihistamines in older urologic patients at risk of urinary retention.
- Do not add dexamethasone on top of a stress-dose steroid regimen.
- Treat PONV as an ERAS outcome — delayed oral intake drives LOS.
References
1. Irani JL, Hedrick TL, Miller TE, et al. "Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery From the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons." Dis Colon Rectum. 2023;66(1):15–40. doi:10.1097/DCR.0000000000002650
2. Weibel S, Rücker G, Eberhart LH, et al. "Drugs for Preventing Postoperative Nausea and Vomiting in Adults After General Anaesthesia — A Network Meta-Analysis." Cochrane Database Syst Rev. 2020;10:CD012859. doi:10.1002/14651858.CD012859.pub2
3. von Peltz CA, Baber C, Nou SL. "Australian Perspective on Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting." Anaesth Intensive Care. 2021;49(4):253–256. doi:10.1177/0310057X211030518
4. Hoshijima H, Miyazaki T, Mitsui Y, et al. "Machine Learning-Based Identification of the Risk Factors for Postoperative Nausea and Vomiting in Adults." PLoS One. 2024;19(8):e0308755. doi:10.1371/journal.pone.0308755
5. Irani JL, Hedrick TL, Miller TE, et al. "Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery (ASCRS/SAGES)." Surg Endosc. 2023;37(1):5–30. doi:10.1007/s00464-022-09758-x
6. Weibel S, Schaefer MS, Raj D, et al. "Drugs for Preventing Postoperative Nausea and Vomiting in Adults After General Anaesthesia — An Abridged Cochrane Network Meta-Analysis." Anaesthesia. 2021;76(7):962–973. doi:10.1111/anae.15295
7. Apfelbaum JL, Silverstein JH, Chung FF, et al. "Practice Guidelines for Postanesthetic Care — Updated Report by the ASA Task Force on Postanesthetic Care." Anesthesiology. 2013;118(2):291–307. doi:10.1097/ALN.0b013e31827773e9